Guidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19: Intellectual property

As a consequence of the review, authorization and oversight of COVID-19 drugs under the Regulations, manufacturers may benefit from intellectual property protections that are available in respect of a submission that results in an NOC.

Données et ressources

Info additionnelle

Champ Valeur
Dernière modification avril 17, 2026, 17:46 (TU)
Créé le avril 17, 2026, 17:46 (TU)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2021-06-24 00:00:00
open_canada_keywords {"fr": ["COVID-19", "pandémie", "médicament COVID-19", "modification", "Règlement sur les aliments et drogues", "médicaments", "fabricants", "présentation", "avis de conformité", "protections de la propriété intellectuelle"], "en": ["COVID-19", "pandemic", "COVID-19 drug", "amendement", "Food and Drug Regulations", "drugs", "manufacturers", "submission", "notice of compliance", "intellectual property protections"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Lignes directrices sur les modifications apportées au Règlement sur les aliments et drogues pour les médicaments contre la COVID-19 : Propriété intellectuelle
update_frequency as_needed